2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

908. Outcomes Research: Myeloid Malignancies: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Vaccines, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Natural Language Processing, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, APL, MDS, MPN, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

6359 Anemia management and survival outcomes among previously treated patients with myelofibrosis receiving luspatercept: A real-world analysis

Gabriela Soriano Hobbs, MD, Yelina Wang, PhD2, Carmelo Alonso, PharmD3, Derek Tang, PhD, MS, BSPharm4, Anandkumar Dubey, PhD5
1 Mass General Brigham Cancer Institute, Boston, MA, United States
2 Bristol Myers Squibb, Princeton, NJ, United States
3 Bristol Myers Squibb, Princeton, NJ, United States
4 Bristol Myers Squibb, Princeton, NJ, United States
5 Bristol Myers Squibb, Princeton, NJ, United States

Introduction: Anemia is a hallmark of myelofibrosis (MF) and is associated with poor quality of life and reduced survival. While erythropoiesis-stimulating agents (ESAs) have shown variable efficacy in patients (pts) who do not require red blood cell (RBC) transfusions and have low serum erythropoietin levels (<500 U/L), responses are limited in pts who require RBC transfusions. Luspatercept (LUSPA), a first-in-class erythroid maturation agent, improved RBC transfusion independence (RBC-TI) and hemoglobin levels in pts with MF-associated anemia in the phase 2 ACE-536-MF-001 (NCT03194542) and phase 3 INDEPENDENCE (NCT04717414) studies. LUSPA is included in clinical guidelines for MF-associated anemia, yet real-world evidence showing its impact on transfusion burden (TB) in pts who require RBC transfusions remains limited. This study evaluated real-world clinical outcomes and treatment (tx) patterns among pts with MF and anemia requiring RBC transfusions receiving LUSPA or ESAs.

Methods: This non-interventional, retrospective cohort study utilized the Optum Clinformatics® Data Mart database to identify adults in the US with a primary or secondary MF diagnosis and anemia diagnosis within 3 months prior to or any time after MF diagnosis through the end of the study period (Jul 1, 2019–Sept 30, 2025). Pts were required to have a TB of 1–2 RBC transfusions in the 12 weeks (wks) prior to the index date (first initiation of LUSPA [after receiving another treatment] or ESA [first line]; after Jan 1, 2020) and ≥6 months of continuous enrollment before and after the index date (or until death). Pt characteristics were balanced by inverse probability of treatment weighting. Key clinical outcomes were overall survival (OS), RBC-TI for ≥12 and ≥16 consecutive wks starting from index date up to Wk 24, ≥50% reduction in RBC TB over any consecutive 12-wk period starting from index date up to Wk 24, and duration of RBC-TI responses.

Results: In the previously treated LUSPA cohort (n=67), median age was 78 years; 54.6% of pts were female and 69.3% had a primary MF diagnosis. Median time from diagnosis to the index date was 9.9 months; 78.9% of pts had 1 RBC transfusion in the 12 wks prior to the index date. Most pts (86.2%) in the LUSPA cohort had received prior anemia-directed tx, including ESAs (99.2%), danazol (9.9%), and iron chelating agent (5.3%), reflecting a heavily pre-treated population. Overall, 23.2% of pts in the LUSPA cohort had overlapping JAKi tx at index.

In the ESA cohort (n=133), median age was 78 years; 50.5% of pts were female and 66.0% had a primary MF diagnosis. Median time from diagnosis to the index date was 8.9 months in the ESA cohort; 82.6% of pts had 1 RBC transfusion during 12 wks prior to the index date. The majority of pts had no prior anemia-directed tx, with only 2 pts having previously received danazol tx. Overall, 26.2% of pts in the ESA cohort had overlapping JAKi tx at index.

In the pre-treated LUSPA cohort, median OS was 26.3 months. RBC-TI ≥12 and RBC-TI ≥16 responses were achieved by 64.7% and 61.7% of pts, respectively; median (IQR) durations of these responses were 11.0 (6.8–15.0) and 12.9 (7.1–16.4) months, respectively. The proportion of pts achieving ≥50% reduction in RBC TB was 68.4%.

In the ESA cohort, median OS was 15.5 months. RBC-TI ≥12 and RBC-TI ≥16 responses were achieved by 57.1% and 51.8% of pts, respectively, with median (IQR) response durations of 9.5 (5.5–19.2) and 11.2 (6.3–20.2) months, respectively. A ≥50% reduction in RBC TB was achieved by 61.6% of pts.

Conclusions: In this real-world analysis, pts with MF-associated anemia who continued to require RBC transfusions achieved durable, clinically meaningful improvements in anemia-related outcomes with LUSPA, including high rates of RBC-TI response lasting ~1 year, substantial reductions in TB, and OS of >2 years. Notably, pts in the LUSPA cohort experienced these benefits despite being heavily pre-treated with prior anemia-directed therapy. Although responses were also observed in the ESA cohort, continued ESA use in pts who require RBC transfusions was associated with modest clinical benefits. These findings support the real-world clinical benefit of LUSPA in pts with MF-associated anemia requiring RBC transfusions and suggest that pts who no longer respond adequately to ESAs may benefit from initiation of LUSPA. Furthermore, earlier initiation of LUSPA, particularly in pts with a lower TB, may help optimize tx outcomes.

Gabriela Soriano Hobbs, MD: Regeneron - Current holder of stock options in a privately-held company; Incyte - Consultancy (Includes expert testimony); PharmaEssentia - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Cogent - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony)